^
    Back
    Association details:
    Biomarker:EZH2 mutation + BCL2 translocation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Excerpt:
    The four subtypes differed significantly in progression-free survival (P = 8.88×10−6) and overall survival (P = 1.70×10−4), with the BN2 and EZB subtypes having much more favorable outcomes than the MCD and N1 subtypes (Fig. 4A and ​and4B).4B). The predicted 5-year overall survival rates for the MCD, N1, BN2, and EZB subtypes were 26%, 36%, 65%, and 68%, respectively.
    DOI:
    10.1056/NEJMoa1801445